CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia

Chimeric antigen receptor (CAR) T cell therapy for the treatment of acute myeloid leukemia (AML) has the risk of toxicity to normal myeloid cells. CD7 is expressed by the leukemic blasts and malignant progenitor cells of approximately 30% of AML patients but is absent on normal myeloid and erythroid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Ther
Main Authors: Gomes-Silva, Diogo, Atilla, Erden, Atilla, Pinar Ataca, Mo, Feiyan, Tashiro, Haruko, Srinivasan, Madhuwanti, Lulla, Premal, Rouce, Rayne H., Cabral, Joaquim M.S., Ramos, Carlos A., Brenner, Malcolm K., Mamonkin, Maksim
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Gene & Cell Therapy 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6318703/
https://ncbi.nlm.nih.gov/pubmed/30391141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2018.10.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados